Total flavonoids from Rhizoma Drynariae (Gusuibu) for treating osteoporotic fractures: implication in clinical practice.
This systematic review was performed to determine the clinical efficacy and safety of total flavonoids from Rhizoma Drynariae (TFRD) for osteoporotic fractures and to provide clear evidence for clinical practice. Eight databases were searched to identify relevant randomized controlled trials (RCTs) until December 2016. Six RCTs involving 846 patients were included. The primary outcomes included fracture recurrence and death. Meta-analysis showed that both the combination therapy and TFRD alone were better than conventional treatments in improving bone mineral density (BMD) value (weighted mean difference [WMD] =3.68, 95% confidence interval [CI]: 0.01 to 0.04, P=0.0002), (WMD =0.14; 95% CI: 0.11 to 0.16; P<0.00001), respectively, and enhancing therapeutic effect (OR =0.25; 95% CI: 0.12 to 0.51; P=0.0002). Thirty-three patients experienced adverse drug reactions (ADRs), none of the ADRs were severe and all were resolved after symptomatic treatments. Gastrointestinal symptoms were the most common ADRs in the usage of TFRD. Overall, the effect of TFRD on osteoporotic fractures was supported by improving BMD and therapeutic effect. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research. Registration number: CRD42017052797.
['Zhang|Yili|Y|', 'Jiang|Junjie|J|', 'Shen|Hao|H|', 'Chai|Yan|Y|', 'Wei|Xu|X|', 'Xie|Yanming|Y|']
D015519:Bone Density D050071:Bone Density Conservation Agents D005260:Female D005419:Flavonoids D006801:Humans D008297:Male D058866:Osteoporotic Fractures D029621:Polypodiaceae D016032:Randomized Controlled Trials as Topic D016896:Treatment Outcome
total flavonoids Rhizoma Drynariae osteoporotic fractures systematic review evidence-based medicine